Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.

Literature DB >> 11959598

Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.

Silke C Mueller¹, Jolanta Majcher-Peszynska, Heiko Hickstein, Astrid Francke, Annette Pertschy, Martin Schulz, Ralf Mundkowski, Bernd Drewelow.

Abstract

The pharmacokinetics of piperacillin-tazobactam were investigated in eight anuric intensive care patients treated by continuous venovenous hemodialysis (CVVHD). The elimination half-life of piperacillin was 4.3 +/- 1.2 h, and that of tazobactam was 5.6 +/- 1.3 h. The contribution of CVVHD to the overall elimination was relevant (>25%) for both drugs.

Entities: Chemical Species

Mesh：

Substances：

Year: 2002 PMID： 11959598 PMCID： PMC127124 DOI： 10.1128/AAC.46.5.1557-1560.2002

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

19 in total

1. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.

Authors: M K Kim; D Xuan; R Quintiliani; C H Nightingale; D P Nicolau
Journal: J Antimicrob Chemother Date: 2001-08 Impact factor: 5.790

2. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report.

Authors: V P Shah; K K Midha; S Dighe; I J McGilveray; J P Skelly; A Yacobi; T Layloff; C T Viswanathan; C E Cook; R D McDowall
Journal: Eur J Drug Metab Pharmacokinet Date: 1991 Oct-Dec Impact factor: 2.441

Review 3. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors: C M Perry; A Markham
Journal: Drugs Date: 1999-05 Impact factor: 9.546

4. High-performance liquid chromatographic determination of tazobactam by precolumn derivatization.

Authors: E Peyrin; Y Guillaume; C Guinchard
Journal: J Chromatogr B Biomed Appl Date: 1995-10-06

Review 5. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors: P Reetze-Bonorden; J Böhler; E Keller
Journal: Clin Pharmacokinet Date: 1993-05 Impact factor: 6.447

6. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment.

Authors: H Derendorf; T Dalla Costa
Journal: Int J Clin Pharmacol Ther Date: 1996-11 Impact factor: 1.366

Review 7. Piperacillin/tazobactam: a critical review of the evolving clinical literature.

Authors: W E Sanders; C C Sanders
Journal: Clin Infect Dis Date: 1996-01 Impact factor: 9.079

8. Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination.

Authors: K P Daniel; L C Krop
Journal: Pharmacotherapy Date: 1996 Mar-Apr Impact factor: 4.705

9. Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment.

Authors: C E Halstenson; M O Wong; C A Johnson; S W Zimmerman; J J Onorato; W F Keane; M Doepner; L Sia; K Tantillo; S Bansal
Journal: J Clin Pharmacol Date: 1994-12 Impact factor: 3.126

10. Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patients.

Authors: E Keller; J Böhler; A Busse-Grawitz; P Reetze-Bonorden; B Krumme; P Schollmeyer
Journal: Clin Nephrol Date: 1995-01 Impact factor: 0.975

17 in total

1. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.

Authors: Seth R Bauer; Charbel Salem; Michael J Connor; Joseph Groszek; Maria E Taylor; Peilin Wei; Ashita J Tolwani; William H Fissell
Journal: Clin J Am Soc Nephrol Date: 2012-01-26 Impact factor: 8.237

Review 2. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors: Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal: Clin Pharmacokinet Date: 2007 Impact factor: 6.447

Review 3. Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors: Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal: Intensive Care Med Date: 2013-09-18 Impact factor: 17.440

4. A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy.

Authors: Sanjoy Ketan Paul; Jason A Roberts; Jeffrey Lipman; Renae Deans; Mayukh Samanta
Journal: Clin Pharmacokinet Date: 2019-02 Impact factor: 6.447

5. Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy.

Authors: J Petersson; C G Giske; E Eliasson
Journal: Antimicrob Agents Chemother Date: 2021-03-18 Impact factor: 5.191

6. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.

Authors: Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez
Journal: Eur J Hosp Pharm Date: 2019-02-27

10. Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors: Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal: Ann Intensive Care Date: 2012-07-28 Impact factor: 6.925